Form to function: current and future roles for atherosclerosis imaging in drug development.
about
Imaging Atherosclerosis.GPR109A and vascular inflammationGlucose metabolic trapping in mouse arteries: nonradioactive assay of atherosclerotic plaque inflammation applicable to drug discoveryPerspectives and opportunities for nanomedicine in the management of atherosclerosis.Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation.Radiolabelled probes for imaging of atherosclerotic plaques.Inflammation imaging in atherosclerosisAdiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques.A fluorescence lifetime spectroscopy study of matrix metalloproteinases-2 and -9 in human atherosclerotic plaque.Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpointsInterleukin 10-coated nanoparticle systems compared for molecular imaging of atherosclerotic lesions.Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging studyMultimodal cardiovascular magnetic resonance quantifies regional variation in vascular structure and function in patients with coronary artery disease: relationships with coronary disease severity.Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis.Quantitative Longitudinal Imaging of Vascular Inflammation and Treatment by Ezetimibe in apoE Mice by FMT Using New Optical Imaging Biomarkers of Cathepsin Activity and α(v)β(3) IntegrinImaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging.Nanocrystal Core Lipoprotein Biomimetics for Imaging of Lipoproteins and Associated Diseases.Assessment of an elastin binding molecule for PET imaging of atherosclerotic plaquesIn-vivo quantitative T2 mapping of carotid arteries in atherosclerotic patients: segmentation and T2 measurement of plaque components.Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.Pathophysiology of coronary artery disease: the case for multiparametric imaging.An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide.Endogenous ceramide contributes to the transcytosis of oxLDL across endothelial cells and promotes its subendothelial retention in vascular wall.VCAM-1-targeting gold nanoshell probe for photoacoustic imaging of atherosclerotic plaque in mice.Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.What is the future for drug development in atherosclerosis and dyslipidaemia?Morphology: bodies, genes, journals.Macrophage detection in aortic aneurysm: the heat is on.Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response.Strong correlation between early stage atherosclerosis and electromechanical coupling of aorta.Identifying needs and opportunities for advancing translational research in cardiovascular disease
P2860
Q26764836-84E8E6AE-FC78-4CE9-87FC-D6EB2F0B8A78Q28287747-7D3730AF-4DDE-4541-A077-47765B33AD47Q28485353-26F7F809-38B6-44F7-AB68-0F01D368903DQ30455490-2A80AA76-6A21-4B6F-B87F-6BC630A6352DQ30484224-1F3374C6-6783-46F7-AA12-07908FB710C4Q30577193-4267E43A-B198-486B-A227-29D90ED8FEF8Q33719461-4CCA85C9-BD61-42C4-81B7-7F1D3C958186Q33960181-72251D06-8101-4C6D-AB84-1EB4A9D006FDQ33965165-69E28A1A-2F28-46D0-B614-23E6D6496FC7Q35124348-9EF723B1-23AD-4002-88C3-32DFF2E351D4Q35249558-C209F218-1015-40CE-A6F2-8F7CB33B90B0Q35303221-1E819D83-47C4-4BB5-9790-6CACEAACF214Q35666715-24869C75-9539-4CF4-BB32-6770ABB2180CQ35936550-A7D12C51-CF67-4226-99BA-750136CB8352Q36355372-04BE285F-EB7F-494F-8791-81F7FD2F112EQ36728733-01D75E84-076E-4F38-B29D-945547613250Q36841990-66B65CDF-5958-41C6-8767-418CF12B21D9Q37025651-536F5C62-1A02-4EAC-82E0-1F07A6F50C25Q37116815-8A5C7759-AA6E-47AA-B9CE-9B26323AFA27Q37338935-49A788AE-A852-40E2-B724-4AEF3893BC01Q37417701-77C96479-7CB7-4ABB-BCBD-61C257DCC82FQ37626229-F605A97A-277C-4FDB-928C-C33FA75C0D11Q37730677-DEE38045-DC64-4F87-A247-6B3272E7292BQ39251732-56D17F48-5FA2-4138-A5D8-3531F5B1F3F8Q39341721-780A876D-78BC-4593-9C6E-74D912AA626BQ40013858-7334A47A-0531-4EAE-AC71-A37FA85E3956Q42558358-55BA75E2-C615-47A9-83B0-08AA7DE6648CQ42719686-535C9B96-D31A-4530-85CD-CDE5371FB42FQ43289695-0A1DF56B-74B7-4C11-BBA6-A331F42276DAQ45397586-E7D3C4F6-8ACC-4EB8-A3C6-C135B79821DBQ51446926-476DA6E2-BFE2-4885-95C9-E6EF433F081BQ56986575-7D6086EC-54AE-4828-83DD-1890681E1BDC
P2860
Form to function: current and future roles for atherosclerosis imaging in drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Form to function: current and ...... s imaging in drug development.
@en
Form to function: current and ...... s imaging in drug development.
@nl
type
label
Form to function: current and ...... s imaging in drug development.
@en
Form to function: current and ...... s imaging in drug development.
@nl
prefLabel
Form to function: current and ...... s imaging in drug development.
@en
Form to function: current and ...... s imaging in drug development.
@nl
P2860
P356
P1476
Form to function: current and ...... s imaging in drug development.
@en
P2093
Alistair C Lindsay
Robin P Choudhury
P2860
P2888
P304
P356
10.1038/NRD2588
P577
2008-05-16T00:00:00Z